ALS Therapy Development Institute

ALS Therapy Development Institute, Neurimmune partner for ALS

Friday, December 6, 2013 12:51 PM

The ALS Therapy Development Institute (ALS TDI) and its wholly-owned subsidiary, Anelixis Therapeutics, a translational medicine and drug development company, have partnered with Swiss biotech company Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig's disease.

More... »

WIRB Copernicus Group

ALS TDI, Gladstone Institutes to discover potential ALS treatments

Wednesday, December 5, 2012 09:44 AM

The ALS Therapy Development Institute (ALS TDI), aimed at developing effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS), and the Gladstone Institutes, a nonprofit biomedical-research organization, have formed a research collaboration to speed the discovery of potential treatments for ALS through the preclinical drug development process.

More... »

CRF Health eCOA webinar series

ALS TDI, Regenesance partner on Lou Gehrig’s disease

Monday, May 7, 2012 12:35 PM

Cambridge, Mass.-based ALS Therapy Development Institute (ALS TDI), one of the largest ALS drug development centers, has entered into a partnership with Netherlands-based biotech Regenesance to investigate a potential treatment for Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

More... »

ALS Therapy to launch phase II trial of TDI 132

Wednesday, February 15, 2012 04:03 PM

The ALS Therapy Development Institute, a nonprofit biotech, will be launching a phase II clinical trial on TDI 132 (fingolimod)—currently used as treatment for multiple sclerosis—as a potential treatment for ALS (Lou Gehrig's disease). 

More... »

Biogen Idec, UCB partner in ALS research

Monday, December 19, 2011 02:39 PM

The ALS Therapy Development Institute (ALS TDI) has formed a research agreement with Biogen Idec and UCB to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's or Motor Neuron Disease. Financial terms of the agreement were not disclosed.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs